Aro Biotherapeutics: Funding, Investors & Team (Aug 2026)
Aro Biotherapeutics, a biotech company located in Philadelphia, is at the forefront of advancing the capabilities of genetic medicines. Their innovative approach revolves around a proprietary protein technology known as Centyrins, allowing them to develop tissue-targeted genetic medicines. Aro Biotherapeutics is actively creating a portfolio of therapeutic candidates based on Centyrins, and collaborating with other industry partners to utilize this technology for precise targeting of treatments for a wide range of diseases.
Aro Biotherapeutics has raised $41.5M across 1 funding round on record, the most recent a Series B of $41.5M announced in Nov 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aro Biotherapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Aro Biotherapeutics Funding Rounds
Aro Biotherapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Aro Biotherapeutics Funding Compared to Other Biotechnology Startups
Aro Biotherapeutics' latest round of $41.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aro Biotherapeutics in Biotechnology and Philadelphia
Companies Similar to Aro Biotherapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Aro Biotherapeutics Funding FAQs
What does Aro Biotherapeutics do?
Aro Biotherapeutics, a biotech company located in Philadelphia, is at the forefront of advancing the capabilities of genetic medicines. Their innovative approach revolves around a proprietary protein technology known as Centyrins, allowing them to develop tissue-targeted genetic medicines. Aro Biotherapeutics is actively creating a portfolio of therapeutic candidates based on Centyrins, and collaborating with other industry partners to utilize this technology for precise targeting of treatments for a wide range of diseases.
How much funding has Aro Biotherapeutics raised?
Aro Biotherapeutics has raised $41.5M across 1 round on record. The most recent is a Series B of $41.5M announced in Nov 2023.
When did Aro Biotherapeutics last raise funding?
Aro Biotherapeutics' most recent funding round on record is a Series B of $41.5M, announced in Nov 2023.
Who is the CEO of Aro Biotherapeutics?
Susan Dillon is listed as CEO at Aro Biotherapeutics.
Where is Aro Biotherapeutics headquartered?
Aro Biotherapeutics is based in Philadelphia, Pennsylvania, United States.
How many employees does Aro Biotherapeutics have?
Aro Biotherapeutics is in the 11-50 employee band.
How does Aro Biotherapeutics' funding compare to other Biotechnology startups?
Aro Biotherapeutics' latest round of $41.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aro Biotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aro Biotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.